Antiapoptotic signaling refers to pathways that reduce or delay programmed cell death in stressed but potentially recoverable cells. MSCs and MSC-derived extracellular vesicles can alter survival pathways through growth factors, cytokines, lipids, proteins, and RNA cargo in experimental systems. Reported effects include modulation of PI3K-AKT, ERK/MAPK, BCL-2-family signaling, caspase activation, and other stress-response pathways. These effects are highly context-dependent. Preventing inappropriate apoptosis may preserve tissue after ischemic, inflammatory, or toxic injury, but suppressing cell death is not universally beneficial; damaged, infected, senescent, or malignant cells may require elimination. Demonstrating an antiapoptotic mechanism therefore requires direct measures of cell death and survival in the relevant tissue and disease context.
Figure 1 placeholder — Antiapoptotic signaling
Oxidative-stress reduction
Oxidative-stress reduction describes a shift in the balance between reactive oxygen species and antioxidant defenses. Excess reactive oxygen species can damage lipids, proteins, DNA, mitochondria, and cellular signaling systems, while physiologic redox signaling is necessary for normal function. MSCs and EVs have been reported to influence antioxidant enzymes, inflammatory oxidant production, mitochondrial function, and redox-sensitive pathways in preclinical models. Measurements may include reactive oxygen species, lipid peroxidation products, glutathione status, superoxide dismutase activity, catalase activity, or oxidative DNA damage. A reduction in one oxidative marker does not by itself establish tissue protection or clinical benefit.
Figure 2 placeholder — Oxidative-stress reduction
Mitochondrial effects
Mitochondrial effects include changes in mitochondrial membrane potential, respiration, ATP production, fission and fusion, biogenesis, mitophagy, calcium handling, and generation of reactive oxygen species. MSC-derived signals and EV cargo can modify mitochondrial stress responses in recipient cells, while living MSCs may also participate in intercellular mitochondrial transfer under selected experimental conditions. Improved mitochondrial measurements can support a mechanism of tissue protection, but mitochondrial function is heterogeneous across tissues and disease states. Demonstrating mitochondrial benefit requires evidence that the observed change is biologically meaningful and linked to tissue function rather than merely a laboratory surrogate.
Figure 3 placeholder — Mitochondrial effects
Autophagy
Autophagy is a regulated cellular recycling process that delivers damaged proteins, organelles, and other cytoplasmic material to lysosomes for degradation and reuse. Selective removal of damaged mitochondria is termed mitophagy. MSCs and EV-associated signals can influence autophagic pathways in experimental models, potentially affecting stress tolerance, inflammation, metabolism, and cell survival. Interpretation requires caution because increased autophagosome number can reflect either increased autophagic activity or blocked downstream degradation. Assessment of autophagic flux, rather than a single static marker, is therefore important when claiming that autophagy mediates a protective effect.
Figure 4 placeholder — Autophagy
Cytoprotection
Cytoprotection is the preservation of cell viability and function during harmful stress. It can result from overlapping antiapoptotic, antioxidant, mitochondrial, autophagic, anti-inflammatory, membrane-stabilizing, and trophic mechanisms. In experimental studies, MSCs or EVs may reduce injury markers or improve survival after hypoxia, ischemia-reperfusion, inflammatory exposure, toxins, or mechanical stress. Cytoprotection should be distinguished from regeneration: keeping endangered cells alive is different from replacing cells that have already been lost. A credible cytoprotective claim requires relevant injury models, appropriate controls, functional outcomes, and evidence that the effect persists beyond a short laboratory observation.
Figure 5 placeholder — Cytoprotection
Metabolic support
Metabolic support refers to mechanisms that help stressed cells maintain energy production, substrate use, redox balance, biosynthesis, and metabolic homeostasis. MSCs and EVs may influence glucose utilization, fatty-acid metabolism, mitochondrial respiration, ATP availability, NAD+/NADH balance, amino-acid metabolism, or metabolic signaling in recipient cells. These effects can interact with inflammation, oxygen availability, mitochondrial health, and tissue perfusion. Metabolic changes are often measured with surrogate assays, and improved ATP or respiration does not automatically translate into restored organ function. Product-specific metabolic mechanisms should therefore be connected to relevant cellular and clinical endpoints.
Figure 6 placeholder — Metabolic support
Clinical takeaway
Tissue protection can occur without replacing damaged cells. MSCs and EVs may influence survival, oxidative stress, mitochondria, autophagy, and metabolism, but these mechanisms overlap and must be demonstrated directly for the specific product and disease.
Injury prevention versus regeneration
Preserving stressed cells before irreversible injury is biologically different from regenerating tissue after cells have been lost. A treatment can be cytoprotective without creating new tissue.
Timing matters
Protective mechanisms are often time-sensitive. An intervention given before, during, or shortly after injury may behave differently from the same intervention given after irreversible tissue loss or established fibrosis.
Surrogate markers
Caspase activity, reactive oxygen species, mitochondrial membrane potential, ATP, autophagy markers, and metabolic readouts can support mechanistic interpretation but remain surrogate endpoints unless linked to meaningful tissue function.
Mechanisms interact
Oxidative stress can damage mitochondria; mitochondrial dysfunction can increase oxidative stress; autophagy and mitophagy can remove damaged components; metabolism influences all of these pathways. Treating these mechanisms as completely independent can be misleading.
Dose and product specificity
The magnitude and direction of tissue-protective effects can vary with cell source, EV composition, manufacturing, dose, route, timing, and recipient biology. Evidence should not be transferred automatically across non-equivalent products.
Clinical interpretation
A lower biomarker of cell injury or oxidative stress does not establish that an intervention prevents disability, restores organ function, or improves survival. Mechanistic and clinical endpoints must remain distinct.
Knowledge gaps
For many investigational MSC and EV products, the relative contribution of antiapoptotic, antioxidant, mitochondrial, autophagic, and metabolic pathways in humans remains uncertain.
Bottom-line evidence statement
Tissue-protection mechanisms are biologically plausible and supported by substantial preclinical literature, but clinical relevance requires product-specific evidence connecting molecular changes to durable tissue and patient outcomes.
Additional controlled terminology
Apoptosis is a form of programmed cell death involving pathways such as PI3K-AKT signaling and caspase activation. Reactive oxygen species contribute to oxidative stress but also participate in normal redox signaling; lipid peroxidation, glutathione, and superoxide dismutase are among measurable redox-related variables. Mitochondrial membrane potential, ATP production, mitochondrial biogenesis, and mitophagy help define mitochondrial state. An autophagosome delivers material toward a lysosome, and autophagic flux describes movement through the complete pathway. Hypoxia and ischemia-reperfusion injury are common experimental stresses. Trophic signaling can support metabolic homeostasis, including NAD+/NADH balance. A surrogate endpoint should not be confused with demonstrated tissue protection or clinical benefit.